Mark Bloch

Statistics

Publications

Citations

217

H-Index

Active since

2015

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Chelsea and Westminster Hospital NHS Foundation Trust

Midway University

Gilead Sciences (United States)

Gordon College

Mark Bloch is an author at Indiana University – Purdue University Indianapolis specializing in clinical pharmacology, antiretroviral therapy, and antiviral therapy.

Publications per year

2015–2024

Publications

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 184 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · 2016 · 23 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)

Karam Mounzer, Jihad Slim, Moti Ramgopal et al. · Clinical Infectious Diseases · 2024 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

1–3 of 3